BioSpecifics Technologies

BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren’s contracture and Peyronie’s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Elbit Systems

eXp World Holdings Inc

Cash is the lifeblood of any business, and provides vitality and strength to a company.

4 Stocks With Rising Cash Flows to Beat Coronavirus Crisis

Is  (BSTC) Outperforming Other Medical Stocks This Year?

Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?

CBIZ

PJT Partners

Gibraltar Industries

Cash provides vitality and strength to a company. It holds the key to the company's existence, development and success, and can indeed be referred to as its lifeblood.

5 Stocks With Rising Cash Flows to Battle Coronavirus Crisis

Coherus BioSciences

DHT Holdings

Euronav

Integer Holdings

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioSpecifics (BSTC) Upgraded to Strong Buy: Here's Why

John Bean Technologies

PagSeguro Digital

As of March 30, the following companies could be undervalued by the market, as their price-earnings ratios are below 20 and their price-earnings to growth (aka PEG) ratios stand below 1.

These Stocks Are Potentially Undervalued

BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioSpecifics Technologies (BSTC) to Report Q3 Results: Wall Street Expects Earnings Growth

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioSpecifics (BSTC) Upgraded to Buy: Here's Why

Endo International

FibroGen

Vaxart

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

Cantel Medical

Champions Oncology

RadNet

TransEnterix

In the long-run, does consistent market timing really matter to be a successful investor?

Simple Market Timing Strategies That Work - August 05, 2019

Biospecifics has recurring royalty revenue expected to grow 10%-15% annually from two Xiaflex indications.

Biospecifics: Upside Not Priced In

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for BioSpecifics Technologies Stock (BSTC)